Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19FN2O3 |
| Molecular Weight | 342.3642 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N[C@@H]1CN(C(=O)C1)C2=CC=C(OCC3=CC=CC(F)=C3)C=C2
InChI
InChIKey=VMAVCCUQTALHOB-INIZCTEOSA-N
InChI=1S/C19H19FN2O3/c1-13(23)21-16-10-19(24)22(11-16)17-5-7-18(8-6-17)25-12-14-3-2-4-15(20)9-14/h2-9,16H,10-12H2,1H3,(H,21,23)/t16-/m0/s1
| Molecular Formula | C19H19FN2O3 |
| Molecular Weight | 342.3642 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sembragiline is a potent, selective, long-acting, and reversible monoamine oxidase B (MAO-B) inhibitor developed as a potential treatment for Alzheimer's disease (AD). Sembragiline was involved in phase II clinical trial to evaluate its the safety, tolerability, and efficacy in patients with moderate AD. In addition, the drug was studied for smoking cessation, however, it failed to demonstrate efficacy during a phase II proof-of-concept trial.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease. | 2017-09 |
|
| Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline. | 2017-03 |
|
| Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). | 2017 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01677754
Participants will receive placebo for RO4602522 orally once daily for 12 months.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:07:03 GMT 2025
by
admin
on
Mon Mar 31 19:07:03 GMT 2025
|
| Record UNII |
K3W9672PNJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
676479-06-4
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
CD-103
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
C152331
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
9900
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
1210947-69-5
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
K3W9672PNJ
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
10246762
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL3707394
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY | |||
|
300000034361
Created by
admin on Mon Mar 31 19:07:03 GMT 2025 , Edited by admin on Mon Mar 31 19:07:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|